您好,欢迎来到试剂仪器网! [登录] [免费注册]
试剂仪器网
位置:首页 > 产品库 > Jolkinolide A
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
Jolkinolide A
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
Jolkinolide A图片
CAS NO:37905-07-0
包装与价格:
包装价格(元)
100mg电议
250mg电议
500mg电议

产品介绍
Jolkinolide A 是一种二萜类化合物,可从大戟属植物 (Euphorbia fischeriana Steud) 的根中提取。Jolkinolide A 具有抗肿瘤活性,通过影响肿瘤组织的血管生成。Jolkinolide A 可显著抑制Akt-STAT3-mTOR信号通路,降低VEGF在 A549 细胞中的表达。
生物活性

Jolkinolide A is a diterpenoid, can be extracted from the roots ofEuphorbia fischeriana Steud. Jolkinolide A exhibits anti-tumor activity, by affecting on angiogenesis of tumor tissues. Jolkinolide A significantly inhibits theAkt-STAT3-mTORsignaling pathway and reduces the expression ofVEGFin A549 cells[1].

IC50& Target

VEGF[1]

体外研究
(In Vitro)

Jolkinolide A (20-100 μg/mL; 24 h) 提高 A549 细胞中 caspase-9 蛋白水平[1]
Jolkinolide A (40-80 μg/mL; 24 h) 降低 A549 细胞中 Akt-STAT3-mTOR 蛋白的表达[1]
Jolkinolide A (20-100 μg/mL; 24 h) 抑制人脐静脉内皮细胞 (HUVEC) 增殖和迁移,促进细胞凋亡[1]

Western Blot Analysis[1]

Cell Line:A549 cells
Concentration:20 μg/mL, 40 μg/mL, 60 μg/mL, 80 μg/mL, and 100 μg/mL
Incubation Time:24 hours
Result:Promoted caspase-9 protein expression in cells at 20-100 μg/mL. Inhibited expression levels of Akt, STAT3, and mTOR proteins in cells at 40-80 μg/mL.
体内研究
(In Vivo)

Jolkinolide A (40 mg/kg; 腹腔注射; 每 3 天一次,持续 2 个月) 抑制小鼠A549细胞异种移植瘤模型中VEGF蛋白的表达[1]

Animal Model:Female BALB/c nude mice (4-5 weeks old) injected with A549 cells[1]
Dosage:40 mg/kg
Administration:Intraperitoneal injection; once every 3 days for 2 months
Result:Significantly inhibited the expression of VEGF protein on the first, 10th, 30th, 45th, and 60th day of administration.
分子量

314.42

Formula

C20H26O3

CAS 号

37905-07-0

结构分类
  • Terpenoids
  • Diterpenoids
来源
  • Plants
  • Euphorbiaceae
  • Euphorbia fischerianaSteud.
运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.